Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 5, 2015, Pages 2093-2098

  Wang, Liang ^a   Wang, Ke Feng ^a   Chang, Bo Yang ^a   Chen, Xiao Qin ^a   Xia, Zhong Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Bortezomib; Efficacy; Multiple myeloma; Peripheral neuropathy; Subcutaneous

Indexed keywords

BORTEZOMIB;

AGED; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE MYELOMA; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; BORTEZOMIB; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MULTIPLE MYELOMA;

EID: 84928577857     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.5.2093     Document Type: Article

References (26)

1. Avet-Loiseau H, Leleu X, Roussel M, et al (2010). Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol, 28, 4630-4.
2. Badros A, Goloubeva O, Dalal J S, et al 2007. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 110, 1042-9.
3. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF 2013. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood, 121, 884-92.
4. Bringhen S, Larocca A, Rossi D, et al 2010. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 116, 4745-53.
5. Chanan-Khan A A, and Giralt S 2010. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol, 28, 2612-24.
6. Durie B G, Harousseau J L, Miguel J S, et al 2006. International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-73.
7. Engelhardt M, Kleber M, Udi J, et al 2010. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma, 51, 1424-43.
8. Harousseau J L, Attal M, and Avet-Loiseau H 2009. The role of complete response in multiple myeloma. Blood, 114, 3139-46.
9. Kapoor P, Kumar S K, Dispenzieri A, et al 2013. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol, 31, 4529-35.
10. Knopf KB, Duh MS, Lafeuille MH, et al 2014. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk, 14, 380-8.
11. Koh Y, Lee S Y, Kim I, et al 2014. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol, 74, 653-7.
12. Kumar SK, Rajkumar SV, Dispenzieri A, et al (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-20.
13. Lu J, Lu J, Chen W, et al (2014). Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J, 4, 239.
14. Mateos M V 2010. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev, 36, 24-32.
15. Moreau P, Pylypenko H, Grosicki S, et al 2011. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol, 12, 431-40.
16. Morgan GJ 2013. Transplants for the elderly in myeloma. Blood, 122, 1332-4.
17. Nooka AK, Kaufman JL, Behera M, et al 2013. Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer, 119, 4119-28.
18. Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson K C 2009. Multiple myeloma. Lancet, 374, 324-39.
19. Reeder CB, Reece DE, Kukreti V, et al 2010. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416-7.
20. Richardson PG, Briemberg H, Jagannath S, et al 2006. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 24, 3113-20.
21. Richardson PG, Delforge M, Beksac M, et al 2012. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 26, 595-608.
22. Roschewski M, Korde N, Wu SP and Landgren O 2013. Pursuing the curative blueprint for early myeloma. Blood, 122, 486-90.
23. Sonneveld P, Goldschmidt H, Rosinol L, et al 2013. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol, 31, 3279-87.
24. Sonneveld P, Schmidt-Wolf I G, van der Holt B, et al 2012. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol, 30, 2946-55.
25. Voorhees P M, Laubach J, Anderson K C and Richardson P G (2013). Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood, 121, 858.
26. Wang A, Duan Q, Liu X, et al 2012. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol, 91, 1779-84.